Skip to main content
SpringerLink
Log in

Platelet activating factor-acetylhydrolase (PAF-AH) activity and HDL levels, but not PAF-AH gene polymorphisms, are associated with successful aging in Sicilian octogenarians

  • Original Article
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Background and aims: Aging is associated with an increased risk of developing atherosclerosis. Subjects over 80 years of age without cardiovascular disease provide a model to investigate the protective factors increasing their resistance to atherosclerotic disease. Platelet-activating factor acetylhydrolase (PAF-AH) is an enzyme associated with low density lipoprotein (LDL) and high density lipoprotein (HDL) inactivating platelet-activating factor (PAF) and preventing LDL oxidation by hydrolysis of oxidized phospholipids. The aim of the present study was to evaluate the contribution of the PAF-AH gene Arg92His, Ile198Thr and Ala379Val polymorphisms to resistance toward developing cardiovascular events in healthy Sicilian octogenarians. Methods: Distribution of PAF-AH genotypes and activity, and biochemical parameters, were compared between 100 octogenarians and 200 healthy adults. Results: The individuals in the elderly group displayed significantly higher levels of HDL-C (p<0.001) and plasma (p<0.001) and HDL (p<0.001) PAF-AH activity. Analysis of PAF-AH genotype distributions showed no significant differences between octogenarians and controls. No differences among PAF-AH genotypes with respect to plasma and HDL PAF-AH activity were found in either group. Conclusions: Our results provide no evidence of a significant association between the PAF-AH gene Arg92His, Ile198Thr and Ala379Val polymorphisms and successful aging in Sicilians. They also emphasize that, in these subjects, aging is characterized by increased levels of PAF-AH activity and HDL-C.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beckman KB, Ames BN. The free radical theory of aging matures. Phisiol Rev 1998; 78: 547–81.

    CAS  Google Scholar 

  2. Azhar S, Cao L, Reaven E. Alteration of the adrenal antioxidant defense system during aging in rats. J Clin Invest 1995; 96: 1414–24.

    Article  PubMed  CAS  Google Scholar 

  3. Lykkesfeldt J, Hagen T, Vinarsky V, Ames BN. Age-associated decline in ascorbic acid concentration, recycling and biosynthesis in rat hepatocytes — reversal with (R)-alpha-lipoic acid supplementation. FASEB J 1998; 12: 1183–9.

    PubMed  CAS  Google Scholar 

  4. Jira W, Spiteller G, Scharamm A. Increase in hydroxy fatty acids in human low density lipoproteins with age. Chem Phys Lipids 1996: 84: 165–73.

    Article  PubMed  CAS  Google Scholar 

  5. Steinberg D, Parthasarathy TE, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modification of low density lipoprotein that increases its atherogenicity. N Engl J Med 1989; 320: 915–24.

    CAS  Google Scholar 

  6. Napoli C, Abete P, Corso G, et al. Increased low-density lipoprotein peroxidation in elderly men. Cor Art Dis 1997; 8: 129–36.

    Article  CAS  Google Scholar 

  7. Hofman A, Grobbe DE, de Jon PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdarm Elderly Study. Eur J Epidemiol 1991; 7: 403–22.

    Article  PubMed  CAS  Google Scholar 

  8. Fried LP, Kronmal RA, Newman AB, et al. Risk factor for 5 year mortality in older adults. JAMA 1998; 279: 585–8.

    Article  PubMed  CAS  Google Scholar 

  9. Rowe JW, Kahn RL. Human aging: usual and successful. Science 1987; 237: 143–9.

    Article  PubMed  CAS  Google Scholar 

  10. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 2003; 42: 93–114.

    Article  PubMed  CAS  Google Scholar 

  11. Elisaf M, Telesepis AD. Effect of hypolipidemic drugs on lipopotein-associated platelet activating factor-acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol 2003; 66: 2069–73.

    Article  Google Scholar 

  12. MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338: 477–87.

    Article  Google Scholar 

  13. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val 279→Phe) is a genetic risk factor for stroke. Stroke 1997; 28: 2417–20.

    Article  PubMed  CAS  Google Scholar 

  14. Yamada Y, Yokota M. Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln 281→Arg mutation. Biochem Biophys Res Commun 1997; 236: 772–5.

    Article  PubMed  CAS  Google Scholar 

  15. Bell R, Collier DA, Rice SQ, et al. Systematic screening of the LDL — PLA2 gene for polymorphic variants and case-control analysis in schizophrenia. Biochem Biophys Res Commun 1997; 241: 630–5.

    Article  PubMed  CAS  Google Scholar 

  16. Kruse S, Mao XQ, Heinzmann A, et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Human Genet 2000; 66: 1522–30.

    Article  CAS  Google Scholar 

  17. Ito S, Noguchi E, Shibasaki M, Yamakawa-Kobayashi K, Watanabe H, Arinami T. Evidence for an association between plasma platelet-activating factor acetylhydrolase deficiency and increased risk of childhood atopic asthma. J Human Genet 2002; 47: 99–101.

    Article  CAS  Google Scholar 

  18. Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994 →T missense mutation in exon 9 of the plasma platelet activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 1998; 47: 177–81.

    Article  PubMed  CAS  Google Scholar 

  19. Abuzeid AM, Hawe E, Humphries SE, Talmud PJ, for the HIFMECH Study Group: Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis 2003; 168: 283–8.

    Article  PubMed  CAS  Google Scholar 

  20. Ninio E, Tregouet D, Carrier JL, et al., for the AtheroGene Investigators. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary disease. Human Mol Gen 2004; 13: 1341–51.

    Article  CAS  Google Scholar 

  21. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183–97.

    Google Scholar 

  22. Kosaka T, Yamaguchi M, Soda Y, et al. Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Clin Chim Acta 2000; 296: 151–61.

    Article  PubMed  CAS  Google Scholar 

  23. Satoh K, Yoshida, Imaizumi T, Takamatsu S, Mizumo S. Platelet activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke. Stroke 1992; 23: 1090–2.

    Article  PubMed  CAS  Google Scholar 

  24. Packard CJ, O’Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 2000; 343: 1148–55.

    Article  PubMed  CAS  Google Scholar 

  25. Blake GJ, Dada N, Fox JC, Manson JE, Ridker P. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001; 38: 1302–6.

    Article  PubMed  CAS  Google Scholar 

  26. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein and risk for incident coronary hearth disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2004; 109: 837–42.

    Article  PubMed  CAS  Google Scholar 

  27. Oei HHS, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke. The Rotterdam Study. Circulation 2005; 111: 570–5.

    Article  CAS  Google Scholar 

  28. Quarck R, De Geest B, Stengel D, et al. Adenovirus-mediated gene transfer of human platelet activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficent mice. Circulation 2001; 103: 2495–500.

    Article  PubMed  CAS  Google Scholar 

  29. Tjoelker LW, Wilder C, Eberhadt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995; 374: 549–53.

    Article  PubMed  CAS  Google Scholar 

  30. Theilmeier G, De Geest B, Van Veldhoven PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apo E-/- mice. FASEB J 2000; 14: 2032–9.

    Article  PubMed  CAS  Google Scholar 

  31. Noto H, Hara M, Karasawa K, et al. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vas Biol 2003; 23: 829–35.

    Article  CAS  Google Scholar 

  32. Serebruany VI, Gurbel PA, Murugesan SR, Lowry DR, Sturm E. Svetlov SI. Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction. Cardiology 1998; 90: 127–30.

    CAS  Google Scholar 

  33. Shoet RV, Anwar A, Jhonston JM, Ccohen JC. Plasma platelet-activating factor acetylhydrolase activity is not associated with premature coronary atherosclerosis. Am J Cardiol 1999; 83: 109–11.

    Article  Google Scholar 

  34. Tselepis AD, Goudevenos JA, Tambaki AP, et al. Platelet aggregatory response to platelet activating factor acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy. Cardiovasc Res 1999; 43: 183–91.

    Article  PubMed  CAS  Google Scholar 

  35. Nikkila M, Keikkinen J. High density lipoprotein cholesterol and longevity. Age Ageing 1990; 19: 119–24.

    Article  PubMed  CAS  Google Scholar 

  36. Burke GL, Arnold AM, Bild DE, et al. Factors associated with healthy aging: the Cardiovascular Health Study. J Am Geriatr Soc 2001; 49: 254–62.

    Article  PubMed  CAS  Google Scholar 

  37. Stafforini DM, Tjoelker LW, Mc Cormick SP, et al. Molecular basis of the interaction between plasma platelet activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 1998; 274: 7018–24.

    Article  Google Scholar 

  38. Watson KE, Hama S, Fonarow GC, Ansell BJ, Navab M, Fogelman AM. Metabolic syndrome patients have higher plasma lipid hydroperoxides and more pro-infiammatory HDL than dyslipidemic control subjects, even with comparable levels of HDL, hs-CRP and paraoxonase activity. Circulation 2004; 110: 1152–8.

    Google Scholar 

  39. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 1998; 273: 6088–95.

    CAS  Google Scholar 

  40. Mackness MI, Arrol S, Abbot C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129–35.

    Article  PubMed  CAS  Google Scholar 

  41. Nofer R, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein F. HDL and arteriosclerosis beyond reverse cholesterol transport. Atherosclerosis 2002; 161: 1–16.

    Article  PubMed  CAS  Google Scholar 

  42. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994; 266: 353–64.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physiology and Nutritional Sciences, University of Messina, Policlinico G. Martino, Italy

    Salvatore Campo

  2. Department of Internal Medicine, University of Messina, Policlinico G. Martino, Via Camiciotti 82, 98123, Messina, Italy

    Maria Adriana Sardo, Antonio Bonaiuto, Carlo Saitta, Maria Castaldo, Maurizio Cinquegrani, Michele Bonaiuto, Simona Cristadoro & Antonino Saitta MD

  3. Institute of Statistical Sciences, University of Messina, Italy

    Giuseppe Trimarchi

  4. Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Policlinico G. Martino, Messina, Italy

    Alessandra Bitto

Authors
  1. Salvatore Campo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Adriana Sardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Trimarchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonio Bonaiuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carlo Saitta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alessandra Bitto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Castaldo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maurizio Cinquegrani
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michele Bonaiuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Simona Cristadoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Antonino Saitta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonino Saitta MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Campo, S., Sardo, M.A., Trimarchi, G. et al. Platelet activating factor-acetylhydrolase (PAF-AH) activity and HDL levels, but not PAF-AH gene polymorphisms, are associated with successful aging in Sicilian octogenarians. Aging Clin Exp Res 20, 171–177 (2008). https://doi.org/10.1007/BF03324764

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03324764

Keywords

Search

Navigation